BioAge Labs Inc.

BIOA | NASDAQ

Price Alert Chart Builder DCF Calculator

$8.25

+$0.16 (+1.98%)

Sep 22, 2026, 12:23 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+1.98%

(1D)

Rating

Updated: Aug 27, 2026

25.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $310.61M

1D Range

8.11 8.40

52W Range

4.90 25.96

Valuation (TTM)

PE -3.40

PB 0.81

EV/EBITDA 0.11

Valuation (NTM)

Forward PE N/A

Forward PEG 0.32

Price Target $34

Cash Flow

FCF Yield -36.8%

SBC Adj. FCF Yield -42.8%

SBC Impact -16.3%

Margins

Gross Margin 99.4%

Operating Margin -1026.3%

FCF Margin -1083.2%

Growth (CAGR)

Revenue 3Y | 5Y 109.3% | N/A

Dil EPS 3Y | 5Y -13.1% | N/A

FCF 3Y | 5Y -44.2% | N/A

Returns

ROA -23.8%

ROE -29.0%

ROIC -28.1%

Financial Health

Net Cash

$318.03M

Current Ratio 17.19

Interest Coverage -378.19

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that ...

Sector Healthcare

Industry Biotechnology

Employees 61

IPO Date Sep 25, 2024

Website bioagelabs.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 5, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$32.50

Upside

+293.94%

Buy (5)

Hold (0)

Sell (0)

Analyst Details ➞